Natixis Advisors LLC Purchases 1,009 Shares of Merit Medical Systems, Inc. (NASDAQ:MMSI)

Natixis Advisors LLC grew its position in Merit Medical Systems, Inc. (NASDAQ:MMSI) by 1.5% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 67,544 shares of the medical instruments supplier’s stock after purchasing an additional 1,009 shares during the quarter. Natixis Advisors LLC owned approximately 0.12% of Merit Medical Systems worth $6,675,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of MMSI. O Shaughnessy Asset Management LLC increased its holdings in Merit Medical Systems by 17.7% in the first quarter. O Shaughnessy Asset Management LLC now owns 3,797 shares of the medical instruments supplier’s stock worth $288,000 after purchasing an additional 572 shares in the last quarter. CANADA LIFE ASSURANCE Co lifted its position in shares of Merit Medical Systems by 5.6% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 62,343 shares of the medical instruments supplier’s stock valued at $4,724,000 after acquiring an additional 3,321 shares during the period. EntryPoint Capital LLC boosted its stake in Merit Medical Systems by 2,666.7% during the first quarter. EntryPoint Capital LLC now owns 913 shares of the medical instruments supplier’s stock worth $69,000 after acquiring an additional 880 shares in the last quarter. CreativeOne Wealth LLC grew its holdings in Merit Medical Systems by 10.3% in the first quarter. CreativeOne Wealth LLC now owns 4,003 shares of the medical instruments supplier’s stock worth $303,000 after purchasing an additional 375 shares during the period. Finally, Lazard Asset Management LLC increased its stake in Merit Medical Systems by 1,147.3% in the first quarter. Lazard Asset Management LLC now owns 7,858 shares of the medical instruments supplier’s stock valued at $594,000 after purchasing an additional 7,228 shares in the last quarter. 99.66% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Piper Sandler reissued an “overweight” rating and set a $110.00 price objective (up previously from $100.00) on shares of Merit Medical Systems in a research report on Monday, September 9th. Bank of America raised their price objective on Merit Medical Systems from $92.00 to $103.00 and gave the company a “neutral” rating in a research note on Monday, September 16th. Needham & Company LLC reaffirmed a “buy” rating and set a $109.00 target price on shares of Merit Medical Systems in a research report on Thursday, October 31st. Barrington Research reissued an “outperform” rating and issued a $114.00 price target on shares of Merit Medical Systems in a research report on Thursday, October 31st. Finally, StockNews.com downgraded shares of Merit Medical Systems from a “buy” rating to a “hold” rating in a report on Sunday, November 3rd. Three equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Merit Medical Systems presently has an average rating of “Moderate Buy” and a consensus target price of $103.36.

Merit Medical Systems Stock Up 0.3 %

MMSI opened at $105.33 on Friday. Merit Medical Systems, Inc. has a fifty-two week low of $65.46 and a fifty-two week high of $106.87. The firm has a market capitalization of $6.14 billion, a P/E ratio of 51.63, a PEG ratio of 2.60 and a beta of 0.89. The company’s 50-day moving average is $98.41 and its 200 day moving average is $90.65. The company has a debt-to-equity ratio of 0.57, a current ratio of 5.36 and a quick ratio of 3.82.

Merit Medical Systems (NASDAQ:MMSI) last posted its earnings results on Wednesday, October 30th. The medical instruments supplier reported $0.86 EPS for the quarter, topping the consensus estimate of $0.80 by $0.06. The firm had revenue of $339.85 million for the quarter, compared to analysts’ expectations of $334.60 million. Merit Medical Systems had a net margin of 9.05% and a return on equity of 15.61%. The company’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same quarter last year, the firm earned $0.75 EPS. Research analysts expect that Merit Medical Systems, Inc. will post 3.36 earnings per share for the current fiscal year.

Insider Buying and Selling at Merit Medical Systems

In other Merit Medical Systems news, CFO Raul Jr. Parra sold 29,646 shares of the business’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $98.02, for a total value of $2,905,900.92. Following the transaction, the chief financial officer now directly owns 16,361 shares in the company, valued at $1,603,705.22. The trade was a 64.44 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director F. Ann Millner sold 12,500 shares of the stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $101.55, for a total transaction of $1,269,375.00. Following the transaction, the director now directly owns 32,391 shares of the company’s stock, valued at $3,289,306.05. This represents a 27.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 3.70% of the company’s stock.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.